Skip to NavigationSkip to content

Mylan looks to hit Teva where it hurts, eyeing slow-release MS treatment

Published on 11/04/18 at 08:35am

Mylan has taken several steps recently that seem intended to hit sales of its big rivals on their key products, first looking at a Botox equivalent and now it has been revealed that it has signed a deal that could see a slow-release Copaxone competitor enter the market.

The partnership involves Mylan teaming up with Israeli-firm, Mapi Pharma, whose lead product is GA Depot, a long-acting Glatiramer Acetate treatment for relapsing-remitting multiple sclerosis. Its major strength over Copaxone is that it could be administered only once a month, should it be approved – this compares favourably to the three-doses per week required by Copaxone.

It was announced that the two companies are preparing to begin recruiting for a Phase 3 trial, as well as beginning the process that will see them apply for IND at the FDA.

Should the drug come through the Phase 3 trial meeting its endpoints then it could likely decimate sales of Copaxone and any generic competitors, including Mylan’s own product.

The financial details of the move were not revealed but Haaretz suggested that $20 million would exchange hands initially.

Mylan President Rajiv Malik commented: “Improving the lives of MS patients around the world is one of Mylan's primary goals. We recognize that medication convenience is very important to the MS community, and we believe that GA Depot, once approved, will provide an important and welcomed treatment option. GA Depot also will add to our already-strong portfolio of central nervous system products. We appreciate the opportunity to work with Mapi Pharma and its successful and proven founder, Ehud Marom, and we believe that our teams are well poised for a successful collaboration as we work through the remaining clinical and regulatory phases to bring this important product to market.”

The financial backing offered by Mylan means that the biotech seems to have averted its decision to go public in the order to secure short-term funding, after it halted a planned $50 million offering.

Ehud Marom, CEO and Chairman of Mapi, commented, “As one of Israel's leading biotech companies, we are pleased and excited to have partnered and collaborated with Mylan in bringing this very important new product to the millions of MS patients around the globe. GA Depot is expected to significantly improve the mode of treatment for patients with MS by reducing the number of injections, easing the treatment burden and increasing patient compliance. We look forward to working with Mylan to bring this important drug to MS patients.”

Ben Hargreaves


The chemically more effective rubber outside matches hydrophilic, so it combines with the hydrophilic exterior of the assignment help website enclosing cement form much bigger. The automatically updated rubberized concrete is also flexible than standard concrete.

Very useful post. This is my first time i visit here. I found so many interesting stuff in your blog especially its discussion. Really its great article. Keep it up. Hero Instinct

Wow! Such an amazing and helpful post this is. I really really love it. It's so good and so awesome. I am just amazed. I hope that you continue to do your work like this in the future also. Text Chemistry

This post is good enough to make somebody understand this amazing thing, and I’m sure everyone will appreciate this interesting things. Relationship Rewrite Method

Very useful post. This is my first time i visit here. I found so many interesting stuff in your blog especially its discussion. Really its great article. Keep it up. 13 Zodiac Signs

Your music is amazing. You have some very talented artists. I wish you the best of success. How To Make Yourself Pee

it's really cool blog. Linking is very useful have really helped How To Turn a Guy On

Hi, I log on to your new stuff like every week. Your humoristic style is witty, keep it up Femto

You re in point of fact a just right webmaster. The website loading speed is amazing. It kind of feels that you're doing any distinctive trick. Moreover, The contents are masterpiece. you have done a fantastic activity on this subject!

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches